Sign In
Buy ALLO
$2.00
-0.0500 (-2.44%)
At Close: Jun 03, 2026
ALLO Rises on Strong MRD Clearance With Cema-Cel in ALPHA3 Study
01:15pm, Tuesday, 14'th Apr 2026
Allogene jumps as cema-cel shows strong MRD clearance and safety in the ALPHA3 study, signaling potential in first-line LBCL treatment.
Traders Purchase High Volume of Allogene Therapeutics Call Options (NASDAQ:ALLO)
01:08am, Tuesday, 14'th Apr 2026
Allogene Therapeutics, Inc. (NASDAQ: ALLO - Get Free Report) was the target of some unusual options trading activity on Monday. Investors acquired 6,076 call options on the stock. This is an increase
Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock
04:01pm, Monday, 13'th Apr 2026
SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced that it intends to offer and sell, in an underwritten public offering and sub
Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell Lymphoma Transcript
Allogene: Early ALPHA3 Data Suggests Potential Paradigm Shift For Cema-Cel In LBCL
12:44pm, Monday, 13'th Apr 2026
Allogene Therapeutics is positioned for a paradigm shift in CAR T therapy with cema-cel, targeting earlier, scalable intervention in high-risk LBCL. ALPHA3 interim data showed 58.3% MRD negativity for
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted Allogene Therapeutics' (NASDAQ: ALLO) interim futility analysis
41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30% MRD Reduction Occurred Rapidly Following Cema-Cel Treatmen
SOUTH SAN FRANCISCO, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC
Short Interest in Allogene Therapeutics, Inc. (NASDAQ:ALLO) Rises By 19.8%
02:29am, Tuesday, 17'th Mar 2026
Allogene Therapeutics, Inc. (NASDAQ: ALLO - Get Free Report) saw a significant increase in short interest in the month of February. As of February 27th, there was short interest totaling 23,927,216 sh
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4
12:25pm, Friday, 13'th Mar 2026
ALLO posts a narrower Q4 loss than expected, cuts expenses and advances key CAR-T studies, with cash projected to fund operations into 2028.
Allogene Therapeutics, Inc. (ALLO) Q4 2025 Earnings Call Transcript
02:22am, Friday, 13'th Mar 2026
Allogene Therapeutics, Inc. (ALLO) Q4 2025 Earnings Call Transcript
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
04:02pm, Thursday, 12'th Mar 2026
SOUTH SAN FRANCISCO, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC
Take the Zacks Approach to Beat the Markets: Starbucks, Amgen, Allogene in Focus
10:01am, Monday, 09'th Mar 2026
ALLO, SBUX and AMGN highlight how Zacks strategies and portfolio picks are delivering strong gains despite recent market volatility.
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update
08:30am, Monday, 02'nd Mar 2026
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC
Allogene Therapeutics, Inc. (ALLO) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
03:04pm, Wednesday, 18'th Feb 2026
Allogene Therapeutics, Inc. (ALLO) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
